RT Journal Article
SR Electronic
T1 Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256571
DO 10.1101/2021.05.04.21256571
A1 McNaughton, Anna L
A1 Paton, Robert S
A1 Edmans, Matthew
A1 Youngs, Jonathan
A1 Wellens, Judith
A1 Phalora, Prabhjeet
A1 Fyfe, Alex
A1 Belij-Rammerstorfer, Sandra
A1 Bolton, Jai S
A1 Ball, Jonathan
A1 Carnell, George
A1 Dejnirattisai, Wanwisa
A1 Dold, Christina
A1 Eyre, David W
A1 Hopkins, Philip
A1 Howarth, Alison
A1 Kooblall, Kreepa
A1 Klim, Hannah
A1 Leaver, Susannah
A1 Lee, Lian
A1 López-Camacho, César
A1 Lumley, Sheila F
A1 Macallan, Derek
A1 Mentzer, Alexander J
A1 Provine, Nicholas
A1 Ratcliff, Jeremy
A1 Slon-Compos, Jose
A1 Skelly, Donal
A1 Stolle, Lucas
A1 Supasa, Piyada
A1 Temperton, Nigel
A1 Walker, Chris
A1 Wang, Beibei
A1 Wyncoll, Duncan
A1 ,
A1 ,
A1 Simmonds, Peter
A1 Lambe, Teresa
A1 Baillie, Kenneth
A1 Semple, Malcolm G
A1 Openshaw, Peter IM
A1 ,
A1 Obolski, Uri
A1 Turner, Marc
A1 Carroll, Miles
A1 Mongkolsapaya, Juthathip
A1 Screaton, Gavin
A1 Kennedy, Stephen H
A1 Jarvis, Lisa
A1 Barnes, Eleanor
A1 Dunachie, Susanna
A1 Lourenço, José
A1 Matthews, Philippa C
A1 Bicanic, Tihana
A1 Klenerman, Paul
A1 Gupta, Sunetra
A1 Thompson, Craig P
YR 2021
UL http://medrxiv.org/content/early/2021/05/07/2021.05.04.21256571.abstract
AB It is unclear whether prior endemic coronavirus infections affect COVID-19 severity. Here, we show that in cases of fatal COVID-19, antibody responses to the SARS-COV-2 spike are directed against epitopes shared with endemic beta-coronaviruses in the S2 subunit of the SARS-CoV-2 spike protein. This immune response is associated with the compromised production of a de novo SARS-CoV-2 spike response among individuals with fatal COVID-19 outcomes.Competing Interest StatementDE declares lecture fees from Gilead. CPT and SG hold funding from Blue Water Vaccines.Funding StatementThis work was supported by the Georg and Emily von Opel Foundation, the National Institute for Health Research (NIHR) [award COCIN01], the Medical Research Council [grant MCPC19059], ME was supported by The Leona M. and Harry B. Helmsley Charitable Trust on May 31, 2021 for the project titled, ICARUS IBD: International study of COVID-19 Antibody Response Under Sustained immune suppression in Inflammatory Bowel Disease. RP also supported by funds provided under Professor RW Snows Wellcome Trust Principal Fellowship (# 212176). Meso Scale Diagnostics (USA) provided loan of equipment, reagents and technical support. JSB was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BBM0112241]. CPT was funded by an ERC research grant UNIFLUVAC and two MRC CiC grants (Ref: BR00140). ALM is funded by a NIHR Research Capability Funding grant. HJK is supported by The Future of Humanity Institute at the University of Oxford DPhil Scholarship program. DE is funded by the Robertson Foundation. The funders played no role in the design, execution or reporting of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood donor samples: The study was approved by the SNBTS Research and Sample Governance Committee IRAS project number 18005. Antenatal samples: Ethical approval was obtained from the South-Central Research Ethics Committee (Ref: 08/H0606/139). 14 of the 22 asymptomatic samples: Ethical approval was given by the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149) and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028). 8 of the 22 asymptomatic samples: Samples from healthcare workers who had asymptomatic SARS-CoV-2 infection were collected as part of the Oxford Translational Gastrointestinal Unit GI Biobank COVID Study 16/YH/0247 [research ethics committee (REC) at Yorkshire & The Humber : Sheffield]. ICU samples (both fatal and non-fatal cohorts) The ICU patients were enrolled as part of an on going prospective observational study AspiFlu (ISRCTN51287266) which has national HRA (CPMS 43440/IRAS 271269) and REC (19/WA/0310) approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request and will be submitted into a suitable repository upon acceptance of the paper.